Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 8;6:e2200245. doi: 10.1200/PO.22.00245

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Methods currently used for a precise diagnosis of patients with cancer and tumor characterization. ^aMethod/design-specific limitations may exist in sensitivity and/or event type or size. ^bOnly when a normal control is included in the test, which is not routine practice. ^cAlthough the approach is genome-wide, the analysis is usually done in targeted way because of the complexity of analysis. CMA, chromosomal microarray; CNAs, copy number aberrations; Diff. Expr., differential expressions; FISH, fluorescence in situ hybridization; GEX, gene expression; HLA, human leukocyte antigen; HRD, homologous recombination deficiency; HRR, homologous recombination repair; MSI, microsatellite instability; PGX, pharmacogenomics; SNVs, single-nucleotide variants; TMB, tumor mutational burden; TME, tumor mutational environment; WES, whole-exome sequencing; WGS, whole-genome sequencing; WGTS, whole-genome and transcriptome sequencing; WTS, whole-transcriptome sequencing.